Exploiting antibody biology for the treatment of cancer

Vidhi Khanna, Jayanth Panyam, Thomas S. Griffith

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Over the last decade, antibodies have become an important component in the arsenal of cancer therapeutics. High-specificity, low off-target effects, desirable pharmacokinetics and high success rate are a few of the many attributes that make antibodies amenable for development as drugs. To design antibodies for successful clinical applications, however, it is critical to have an understanding of their structure, functions, mechanisms of action and pharmacokinetic/pharmacodynamic properties. This review highlights some of these key aspects, as well as certain limitations encountered, with monoclonal antibody therapy. Further, we discuss rational combination therapies for clinical applications, some of which could help overcome the limitations.

Original languageEnglish (US)
Pages (from-to)255-267
Number of pages13
JournalImmunotherapy
Volume12
Issue number4
DOIs
StatePublished - Mar 2020

Keywords

  • cancer
  • combinations
  • mechanisms
  • monoclonal antibodies
  • structure

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Exploiting antibody biology for the treatment of cancer'. Together they form a unique fingerprint.

Cite this